Entera Bio Ltd (ENTX)

$2.33 -0.05 (-2.10%)
Market Cap 83.38M
Revenue (ttm) 0.00
Net Income (ttm) -8.89M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 68,900
Avg Vol 164,444
Day's Range N/A - N/A
Shares Out 35.79M
Stochastic %K 38%
Beta 1.49
Analysts Strong Sell
Price Target $10.00

Latest News on ENTX

Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 27, 2025, 8:00 AM EST - 3 days ago

Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

Nov 8, 2024, 4:05 PM EST - 2 months ago

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

Sep 25, 2024, 8:30 AM EDT - 4 months ago

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

Entera Bio to Participate in Upcoming Investor and Scientific Conferences

Aug 20, 2024, 8:00 AM EDT - 5 months ago

Entera Bio to Participate in Upcoming Investor and Scientific Conferences

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

Aug 9, 2024, 4:05 PM EDT - 6 months ago

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

May 15, 2024, 8:00 AM EDT - 9 months ago

Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

May 13, 2024, 7:00 AM EDT - 9 months ago

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates

May 10, 2024, 4:10 PM EDT - 9 months ago

Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Apr 8, 2024, 8:30 AM EDT - 10 months ago

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

Mar 26, 2024, 8:30 AM EDT - 11 months ago

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Mar 20, 2024, 8:00 AM EDT - 11 months ago

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Mar 8, 2024, 4:05 PM EST - 11 months ago

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mar 4, 2024, 8:30 AM EST - 11 months ago

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 30, 2024, 8:30 AM EST - 1 year ago

Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

Jan 3, 2024, 8:00 AM EST - 1 year ago

Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025

Dec 26, 2023, 8:00 AM EST - 1 year ago

Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025

Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform

Nov 29, 2023, 8:30 AM EST - 1 year ago

Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

Nov 14, 2023, 7:30 AM EST - 1 year ago

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis

Nov 9, 2023, 2:30 PM EST - 1 year ago

Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis

Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting

Oct 16, 2023, 8:00 AM EDT - 1 year ago

Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting

Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes

Sep 12, 2023, 8:30 AM EDT - 1 year ago

Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes

Entera Bio to Participate in Upcoming Investor Conferences

Sep 5, 2023, 8:00 AM EDT - 1 year ago

Entera Bio to Participate in Upcoming Investor Conferences

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

Aug 16, 2023, 8:30 AM EDT - 1 year ago

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

Entera Bio Announces Q2 2023 Financial Results and Corporate Updates

Aug 11, 2023, 4:05 PM EDT - 1 year ago

Entera Bio Announces Q2 2023 Financial Results and Corporate Updates

Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors

Jun 7, 2023, 7:30 AM EDT - 1 year ago

Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors

Entera Bio Announces Q1 2023 Financial Results and Corporate Updates

May 5, 2023, 4:05 PM EDT - 1 year ago

Entera Bio Announces Q1 2023 Financial Results and Corporate Updates

Entera's Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

May 3, 2023, 9:34 AM EDT - 1 year ago

Entera's Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera's Clinical and Scientific Advisory Board

Apr 26, 2023, 8:30 AM EDT - 1 year ago

Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera's Clinical and Scientific Advisory Board

Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program

Apr 3, 2023, 7:00 AM EDT - 1 year ago

Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program

Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022

Mar 31, 2023, 4:00 PM EDT - 1 year ago

Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022

Entera Bio Regains Compliance with Nasdaq Listing Requirements

Mar 23, 2023, 9:27 AM EDT - 2 years ago

Entera Bio Regains Compliance with Nasdaq Listing Requirements

Entera Bio Announces FDA's Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis

Feb 15, 2023, 10:00 AM EST - 2 years ago

Entera Bio Announces FDA's Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis

Entera Bio to Participate in the SVB Securities Global Biopharma Conference

Feb 13, 2023, 9:00 AM EST - 2 years ago

Entera Bio to Participate in the SVB Securities Global Biopharma Conference

Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

Nov 10, 2022, 4:15 PM EST - 2 years ago

Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis

Oct 6, 2022, 7:00 AM EDT - 2 years ago

Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis

Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613's Potential Impact on Wednesday, September 28th @ 10am ET

Sep 21, 2022, 8:30 AM EDT - 2 years ago

Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613's Potential Impact on Wednesday, September 28th @ 10am ET

Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference

Sep 12, 2022, 4:30 PM EDT - 2 years ago

Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference

Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting

Sep 12, 2022, 6:30 AM EDT - 2 years ago

Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting

Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022

Aug 11, 2022, 6:30 AM EDT - 2 years ago

Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022

Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting

Jul 26, 2022, 7:30 AM EDT - 2 years ago

Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting

Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO

Jul 18, 2022, 9:23 AM EDT - 2 years ago

Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO

Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position

Jul 18, 2022, 7:05 AM EDT - 2 years ago

Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position

Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company's President of Research & Development to Pursue Outside Opportunities

Jun 17, 2022, 5:00 PM EDT - 2 years ago

Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company's President of Research & Development to Pursue Outside Opportunities

Entera Bio Ltd. (ENTX) CEO Spiros Jamas on Q1 2022 Results - Earnings Call Transcript

May 18, 2022, 2:34 PM EDT - 2 years ago

Entera Bio Ltd. (ENTX) CEO Spiros Jamas on Q1 2022 Results - Earnings Call Transcript

Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights

May 12, 2022, 8:00 AM EDT - 2 years ago

Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights

Entera Bio's (ENTX) CEO Spiros Jamas on Q4 2021 Results - Earnings Call Transcript

Mar 8, 2022, 11:09 AM EST - 3 years ago

Entera Bio's (ENTX) CEO Spiros Jamas on Q4 2021 Results - Earnings Call Transcript

Entera Bio Reports Financial Results for the Year Ended December 31, 2021

Mar 8, 2022, 6:30 AM EST - 3 years ago

Entera Bio Reports Financial Results for the Year Ended December 31, 2021

Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022

Mar 3, 2022, 9:50 AM EST - 3 years ago

Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022

Entera Bio to Present at Aegis Virtual Conference on February 23rd

Feb 17, 2022, 8:30 AM EST - 3 years ago

Entera Bio to Present at Aegis Virtual Conference on February 23rd

Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint

Jan 4, 2022, 8:30 AM EST - 3 years ago

Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint